Opus Genetics partners with Global RDH12 Alliance for OPGx-RDH12; $1.6M funding

Opus Genetics, Inc.

Agreement with RDH12 Fund for Sight and Eyes on the Future provides up to $1.6M for OPGx-RDH12 development.
Partnership includes risk-sharing structure and performance-based milestones; IND filing targeted by late 2025.
If milestones missed, Funding Parties can exercise a non-exclusive license; Opus retains right to negotiate exclusive license back.
During term, Opus cannot grant exclusive U.S. license to a third party without Funding Parties' consent.
Term ends upon dosing three patients in Phase 1a/2b or first commercial sale, or if exclusive global licensee assumes obligations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.